Bone Biologics Corp Files 8-K: Material Definitive Agreement

TL;DR

BBLG signed a big deal, details in the 8-K.

AI Summary

On March 4, 2024, Bone Biologics Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company, headquartered in Burlington, MA, is involved in the orthopedic, prosthetic & surgical appliances & supplies industry.

Why It Matters

This filing indicates a significant new agreement for Bone Biologics Corp, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Bone Biologics Corporation (company) — Registrant
• March 4, 2024 (date) — Date of earliest event reported
• Burlington, MA (location) — Company Headquarters
• 3842 (industry_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
• $2.56 — at a combined public offering price of $2.56 per Share and accompanying Warrant and
• $2.559 — at a combined public offering price of $2.559 per Pre-Funded Warrant and accompanying
• $2.43 — the Warrants have an exercise price of $2.43 per share of Common Stock, are exercisa
• $1.5 m — ny from the Offering were approximately $1.5 million, after deducting Placement Agent'
• $10,000 — accountable expenses in an amount up to $10,000, its legal fees and expenses and other
• $100,000 — -pocket expenses in the amount of up to $100,000, and its clearing expenses in the amoun
• $15,950 — its clearing expenses in the amount of $15,950. The Company also issued the Placement
• $3.20 — arrants have an exercise price equal to $3.20 and have a term of five years from the

Filing Documents

• form8-k.htm (8-K) — 57KB
• ex4-1.htm (EX-4.1) — 121KB
• ex4-2.htm (EX-4.2) — 123KB
• ex4-3.htm (EX-4.3) — 123KB
• ex10-1.htm (EX-10.1) — 290KB
• ex99-1.htm (EX-99.1) — 13KB
• ex99-2.htm (EX-99.2) — 13KB
• ex99-1_001.jpg (GRAPHIC) — 14KB
• ex99-2_001.jpg (GRAPHIC) — 14KB
• 0001493152-24-009033.txt ( ) — 1138KB
• bblg-20240304.xsd (EX-101.SCH) — 4KB
• bblg-20240304_def.xml (EX-101.DEF) — 26KB
• bblg-20240304_lab.xml (EX-101.LAB) — 36KB
• bblg-20240304_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: March 6, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR